Anti-LAG-3 Antibodies for Selective T Cell Activation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing technologies have not effectively addressed the need for developing agents that modulate the activity of LAG-3 in downregulating an immune response, particularly for cancer immunotherapy and treatment of chronic infections.
Innovation Solution
Development of antibody molecules, such as humanized antibodies, that bind to Lymphocyte Activation Gene-3 (LAG-3) with high affinity and specificity, addressing the technical problem of the immune system. These molecules are designed to address the need for developing agents that modulate its activity to activate the immune system, specifically for cancer immunotherapy and treatment of chronic infections.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing technologies are used to develop agents that modulate LAG-3 activity, then the immune system remains downregulated, but the desired activation of T cell responses and anti-tumor responses is not achieved
Solution Approach 1:
The patent applies parameter changes by developing antibody molecules with specific binding characteristics to LAG-3. The antibodies are engineered to bind with high affinity to LAG-3 while minimizing binding to CD4, representing a change in binding parameters. This selective binding modulation enables the activation of T cell responses and anti-tumor responses that were not achieved with existing technologies
2Reliability
If antibody molecules are designed to bind to LAG-3 with high affinity, then interaction with MHC class II molecules is inhibited and T cell responses are stimulated, but binding to CD4 and other unwanted interactions may occur
Solution Approach 1:
The patent applies local quality by engineering antibody molecules with differentiated binding properties at different sites. The antibodies are designed to have high affinity and specificity for LAG-3 while minimizing binding to CD4 and other unwanted interactions. This localized optimization of binding characteristics at the antibody-LAG-3 interface enables selective modulation of LAG-3 activity without triggering unwanted immune responses or off-target effects
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The antibody molecules effectively bind to LAG-3 with high affinity, inhibiting its interaction with MHC class II molecules, thereby stimulating antigen-specific T cell responses and enhancing anti-tumor responses, while minimizing binding to CD4 and other unwanted interactions.
Implementation Method 1
antibody molecules that bind to Lymphocyte Activation Gene-3 (LAG-3) with high affinity and specificity
Data Source
AI summary
Antibody molecules that specifically bind to LAG-3 are disclosed. The anti-LAG-3 antibody molecules can be used to treat, prevent and/or diagnose cancerous or infectious disorders.